Skip to main content
. 2008 Oct 31;7:225. doi: 10.1186/1475-2875-7-225

Figure 2.

Figure 2

Observed and predicted plasma concentration-time profiles (median values) of fosmidomycin in patients with sensitive responses in Group-I (fosmidomycin 900 mg plus 300 clindamycin every 6 hours for 3 days; N = 23) and Group-II (fosmidomycin 1800 mg plus 600 mg clindamycin every 12 hours; N = 45). The curve represents simulated concentration-time profile based on the median concentrations in each group.